Defence, Cdn Nuclear Laboratories expand work program

Executive Summary

• Defence Therapeutics has expanded its existing collaboration with Canadian Nuclear Laboratories (CNL) to accelerate its proprietary radiopharmaceutical pipeline.
• The expansion includes initiating multiple new radioisotope programs leveraging Defence's proprietary "Accum" platform, moving beyond the current Accum-enhanced radio-immunoconjugate program.
• Critical results from the current collaboration are being generated to support candidate selection and prepare for first-in-human clinical studies.

Key Details

• Parties Involved: Defence Therapeutics Inc. and Canadian Nuclear Laboratories (CNL).
• Scope of Expansion: The collaboration is expanding from a single program to multiple other radioisotope programs.
• Current Program Status: The existing Accum-enhanced radio-immunoconjugate program is approaching a key inflection point, with critical results being generated to support candidate selection and preparation for first-in-human clinical studies.
• Technology Platform: Defence’s proprietary "Accum" platform enables active intracellular and nuclear transport, designed to maximize efficacy by ensuring radioactive payloads reach the cell nucleus to induce lethal DNA damage while reducing toxicity.
• Strategic Priority: Radiopharmaceuticals are now identified as one of the company's top development priorities, alongside its Antibody-Drug Conjugate (ADC) program.
• Objective: To rapidly expand the radiopharmaceutical portfolio and build a strong, proprietary pipeline in precision intracellular drug delivery.

Notable Quotes

• Sebastien Plouffe, CEO: "This collaboration with CNL has become a cornerstone of our radiopharmaceutical strategy... By deepening our work with CNL and leveraging their world-class nuclear science expertise, we are building a strong, proprietary pipeline in this space and accelerating our path toward the clinic."
• Dr. Monica Regalbuto, VP, Science and Technology at CNL: "We have worked in close collaboration with Defence on their flagship program, delivering the technical results they require, and we are proud to contribute meaningfully to the advancement of their radiopharmaceutical pipeline... We look forward to contributing our nuclear science expertise to help advance these programs toward the clinic."